- Home
- Equipment
- usa new york
- cell gene therapy
Show results for
Refine by
Cell Gene Therapy Equipment Supplied In Usa New York
15 equipment items found
Manufactured by:Altucell, Inc. based inNew York, NEW YORK (USA)
Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the therapeutic potential of cells to treat serious diseases without the need for immunosuppression. Altucell has developed patented, proprietary engineered cells that are combined with a patented encapsulation technology to create effective ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Our convenient, automated thawing device, for use by clinicians at point of care, offers a reliable and simple thawing method that can safeguard the integrity of the supply chain. This is key to maintaining the potency and consistency of a cell product, because, unlike many traditional drugs, cell therapies must be thawed before being administered to a patient. However, the most commonly used ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-200, our DeltEx DRI, is a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors. This is the first genetically engineered gamma-delta T cell therapy to be administered to patients and our initial indication is newly diagnosed Glioblastoma (GBM). Since 2005 the standard of care treatment for GBM has been surgical resection followed by radiation ...
Manufactured by:Taconic Biosciences, Inc. based inRensselaer, NEW YORK (USA)
The Abb mouse was developed in the laboratory of Michael J. Grusby et al. of the Harvard School of Public Health. The model was created by targeting the H2-Ab1 gene in ES-D3 cells and injecting the targeted ES cells into C57BL/6 blastocysts. Resultant chimeras were backcrossed to C57BL/6 for 4 generations (N4). Taconic received stock from Tufts University in December 1991, and the mice were ...
Manufactured by:Adaptive Biotechnologies based inSeattle, WASHINGTON (USA)
We are currently leveraging our TCR discovery capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our end-to-end capabilities for the development of cellular therapies and vaccines. TruTCR is summarized in the figure ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
MPC-25-IC is Mesoblast’s Phase 2 product candidate for the treatment of acute myocardial infarction. This is the first clinical study to evaluate an allogeneic cellular therapy delivered by intracoronary infusion in patients who have suffered an acute myocardial ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
Remestemcel-L is being developed for inflammatory diseases in children and adults including the treatment of acute graft versus host disease (aGVHD), a potentially life-threatening complication of an allogeneic bone marrow transplant (BMT). Currently, there are no products currently approved in the United States for treatment of steroid-refractory aGVHD in children under 12, and off-label options ...
Manufactured by:Tactiva Therapeutics based inBuffalo, NEW YORK (USA)
Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient’s own immune cells to target and destroy cancer cells. Typically, starting with a few immune cells derived from the patient’s blood, billions of cancer fighting immune cells are manufactured in a special facility, and given back to the ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is the first clinical trial of an expanded and activated allogeneic gamma delta T cell ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is currently in a Phase I clinical trial to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and in development to ...
Manufactured by:Protara Therapeutics, Inc. based inNew York, NEW YORK (USA)
TARA-002 is an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and Taiwan by Chugai Pharmaceutical Co., ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal antibody against a target on the surface of AML ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
Originally developed for in-house testing, the company’s Advanced peripheral blood Hematopoietic Chimera (“ApbHC”) is a novel type of humanised mouse that presents several advantages over existing mouse models. It has applications for disease modelling and drug development, and potentially for ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
Our DeltEx platform has enabled a deep pipeline of preclinical and clinical product candidates, which are designed to effectively target and potentially eradicate disease, to improve patient ...
Manufactured by:BlueRock Therapeutics based inCambridge, MASSACHUSETTS (USA)
With our cell+gene platform, BlueRock is aiming to redefine the very way we treat disease, moving from addressing mere symptoms to restoring health lost to cell damage or degeneration. Instead of prescribing a pill to treat tremors in patients with Parkinson’s, we might restore the chemical messengers that were destroyed, addressing tremors at the source. Those who have suffered a heart ...